In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsIn vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian CancerClinical Breast MR Using MRS or DWI: Who Is the Winner?Key Players in Choline Metabolic Reprograming in Triple-Negative Breast CancerMRS-based Metabolomics in Cancer Research.Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA.Magnetic resonance in the detection of breast cancers of different histological types.The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging.Proton Magnetic Resonance Spectroscopy in adult cancer patients with delirium.Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy1H-MR spectroscopy of suspicious breast mass lesions at 3T: a clinical experience.In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literaturePET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging.Advanced MRI Techniques in the Evaluation of Complex Cystic Breast LesionsInterplay of choline metabolites and genes in patient-derived breast cancer xenografts.Molecular and functional imaging of breast cancer.Current Status and Future Prospects of Proton MR Spectroscopy of the Breast with a 1.5T MR Unit.Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.1H- and 31P-myocardial magnetic resonance spectroscopy in non-obstructive hypertrophic cardiomyopathy patients and competitive athletes.In vivo post-contrast 1H-MRS evaluation of malignant and benign breast lesions: a meta-analysis.Activation of Phosphatidylcholine-Specific Phospholipase C in Breast and Ovarian Cancer: Impact on MRS-Detected Choline Metabolic Profile and Perspectives for Targeted TherapyDiffusion weighted MRI and spectroscopy in invasive carcinoma of the breast at 3Tesla. Correlation with dynamic contrast enhancement and pathologic findings.Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: an MRI and in vivo proton MRS study.Differential diagnosis between malignant and benign breast lesions using single-voxel proton MRS: a meta-analysis.¹H-magnetic resonance spectroscopy of the breast at 3.0-T: comparison of results obtained before and after administration of gadolinium-based contrast agent.The contribution of diffusion tensor imaging and magnetic resonance spectroscopy for the differentiation of breast lesions at 3TApplication value of 3T 1H-magnetic resonance spectroscopy in diagnosing breast tumorsMagnetic resonance spectroscopy of the breast at 3T: pre- and post-contrast evaluation for breast lesion characterization
P2860
Q26740567-7DCF1D98-11EF-43B5-ADE2-5E0B03C44272Q26742109-B9760E9D-A325-4AB3-B90D-03BCE5E6B42AQ28072837-ABCB8753-2984-47EF-A510-F706999548FFQ28074613-477CC1A6-2128-4BA0-B13E-04AB589E5AC4Q30842175-A95B3AA6-2875-4B0F-8F61-B252F1441E9BQ33714951-89C1BAF3-EEB2-4327-9480-4E3934313FDBQ33873362-D9A9DD01-B35C-4F3C-B422-7F464DAEAB42Q34072785-A8240158-1FF1-4E45-972E-1A177DCF971BQ34538255-2DC9B6CC-98D7-42C4-AE75-3834AA2299DEQ35095985-1A6878AA-C441-4BAB-B446-88A47B7F0ADAQ36226344-D45CA97F-1CAF-4C7F-BCBA-2B07E49564A3Q36245493-CE6AF2F3-AB8D-4300-8AB1-62E42D4AC09AQ36357752-76821B25-3B74-4954-BBD3-0719E4228301Q36992150-ABAAF3CF-D166-49EF-B462-006BC29227A3Q37689772-5472DEFF-B221-4317-8E33-31E3A2500FB3Q37776141-17C0995C-A778-452E-8661-FD604D5B0EAFQ37800802-CBC478ED-8723-4F66-9FCB-187F95C11865Q38422342-8E1603F1-8BDC-4EAC-9A5E-8B14C9E451E9Q39030000-02CCB6E3-6BBE-46A2-ADAF-95C60DCC83A3Q39122457-7FD68C7A-47F2-4C5B-94C0-0A00049FA9AFQ40572969-01F3E224-D10A-4413-BEED-267AFFC98432Q45369159-AC7EA771-63B3-41F6-A030-2DEC7AEEEE34Q51458748-F2E8B3A5-139E-4028-AB95-301F36A9D408Q53138050-FD38A6D7-E641-4912-858A-97237C941DE8Q53190792-E0F6F321-C9D8-4C1F-8B79-9818B20DD7E3Q57742687-A733BF5E-A756-4F05-9ECB-758FE75EE5AEQ57742695-5FB3D7A3-9713-40AA-B116-AFB43E38E922Q58915029-E648C1B3-43DE-4490-86F2-6F9D3301D9A4
P2860
In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
In vivo proton MR spectroscopy ...... ral as a marker of malignancy.
@ast
In vivo proton MR spectroscopy ...... ral as a marker of malignancy.
@en
type
label
In vivo proton MR spectroscopy ...... ral as a marker of malignancy.
@ast
In vivo proton MR spectroscopy ...... ral as a marker of malignancy.
@en
prefLabel
In vivo proton MR spectroscopy ...... ral as a marker of malignancy.
@ast
In vivo proton MR spectroscopy ...... ral as a marker of malignancy.
@en
P50
P356
P1476
In vivo proton MR spectroscopy ...... ral as a marker of malignancy.
@en
P2093
Franca Podo
Marianne Vorbuchner
P304
P356
10.2214/AJR.07.3521
P407
P577
2009-06-01T00:00:00Z